7 Jul 2022 11:07
7 July 2022
ValiRx PLC ("ValiRx" or the "Company")
Directors' Dealing
ValiRX, a life science company focusing on early-stage cancer therapeutics and women's health, announced 30 June 2022 that certain directors confirmed their intention to participate in the Placing that was announced on that date.
The table below sets out details of their participation in the Placing at a price of 10 pence per share.
Director | Ordinary Shares Purchased | Resultant Shareholding | % of Issued Share Capital |
Suzanne Dilly | 100,000 | 416,668 | 0.46% |
Martin Lampshire | 100,000 | 144,000 | 0.16% |
Kevin Cox | 100,000 | 372,333 | 0.41% |
Gerry Desler | 25,000 | 128,668 | 0.14% |
*** ENDS ***
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.
For more information, please contact:
ValiRx plc
Dr Suzanne Dilly, CEO
| Tel: +44 (0) 2476 796496 www.valirx.com Suzanne.Dilly@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray/Jo Turner/Ludovico Lazzaretti
| Tel: +44 (0) 20 7213 088 |
Cenkos Securities Limited (Joint Broker)
Russell Kerr/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate Finance) | Tel: +44 (0) 20 7397 8900 |
Turner Pope Investments (TPI) Limited (Joint Broker)
James Pope / Andy Thacker | Tel: +44 (0) 20 3657 0050
|
Notes for Editors
About ValiRx
ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.
With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.
Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/
The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||||||
a. | Name |
| |||||||||||
2 | Reason for notification | ||||||||||||
a. | Position/Status | a) Director b) Director c) Director d) Director | |||||||||||
b. | Initial notification/ Amendment | Initial notification | |||||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||||
a. | Name | ValiRx PLC | |||||||||||
b. | LEI |
| |||||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||||
a. | Description of the financial instrument, type of instrumentIdentification Code | Ordinary Shares
ISIN: GB00BLH13C52 | |||||||||||
b. | Nature of the transaction | Purchase of shares as part of the Placing | |||||||||||
c. | Price(s) and volume(s) | ||||||||||||
Price(s) | Volume(s) | ||||||||||||
|
| ||||||||||||
d. | Aggregated information - Aggregated Volume - Price |
N/A
| |||||||||||
e. | Date of the transaction |
| |||||||||||
f. | Place of the transaction | London, UK
| |||||||||||
ValiRx (VAL)